It’s hard to believe it’s been almost a decade since my last post here — a post about what I would change about the allergy community. Back then, I wrote it from a place of frustration, love, and hope. A lot has changed since 2017, both in the allergy world and in my own life. I took a long break from blogging, but something kept pulling me back: the incredible community we’ve built across countries, platforms, and experiences.
So today — for everyone who’s been here since day one, for those who are new, and for readers from around the world — I want to talk about what’s truly changed in the allergy world since 2017, where progress has been made globally, and what still needs to change. This isn’t just a list — it’s a reflection grounded in lived experience, science, and community voices.
- Awareness Has Shifted — But We’re Not Done
Awareness of food allergies isn’t new anymore. In 2017, many schools and workplaces were just beginning to understand what an epinephrine auto-injector was. Today, there’s far more public recognition — especially in countries like the United States, Canada, the U.K., Australia, and parts of Europe.
In the United States, laws around allergen disclosure in schools and updated labeling requirements on food packaging have created a safer baseline for many families.
In the United Kingdom and EU countries, improvements in Allergen Information Regulations have made cross-contact warnings and ingredient transparency more common.
Countries like Canada have updated their priority allergen lists and labeling standards, bringing them closer in line with global best practices.
This increased awareness has helped reduce some of the fear of the unknown that was so common in 2017. But awareness does not yet equal understanding — and that’s still where a lot of work needs to be done.
- Medical Advances: More Choices, More Questions
One of the biggest changes since 2017 has been the evolution of medical approaches to managing food allergies:
Oral Immunotherapy (OIT)
Oral Immunotherapy has become more widely accepted as an option for desensitizing certain food allergies in both children and adults. It’s no longer a fringe treatment — it’s being offered in clinics across the U.S., Canada, parts of Europe, and Australia. OIT can reduce the severity of reactions, but it’s not a cure, and it isn’t right for everyone. Talking to a specialist, weighing benefits and risks, and monitoring expectations remain essential.
Standardized Peanut Oral Immunotherapy: Palforzia
Oral immunotherapy (OIT) has existed for years, but Palforzia became the first FDA-approved, standardized peanut protein therapy for children ages 1–17.
It reduces the severity of reactions from accidental exposure. It is not a cure. It requires daily dosing and careful medical supervision.
For some families, it brings peace of mind. For others, it’s not the right fit. And that’s okay.
Biologic Therapy: Xolair (Omalizumab)
In 2024, Xolair became the first biologic therapy approved to help reduce allergic reactions from accidental exposure to multiple foods — including peanut, milk, egg, wheat, and others.
It works by targeting IgE antibodies, the antibodies responsible for triggering allergic reactions. Instead of focusing on one specific food, this approach reduces overall reaction risk across multiple allergens.
For families managing several food allergies, this was a major milestone.
Needle-Free Epinephrine: Neffy
Also approved in 2024, Neffy became the first nasal epinephrine spray for treating severe allergic reactions (anaphylaxis).
For many in our community — especially children or those with needle anxiety — this represents a meaningful emotional shift. Traditional auto-injectors remain essential, but having a needle-free option expands accessibility and comfort.
New Studies on Prevention
Since 2017, research has grown on early introduction of allergenic foods to infants — especially peanuts — as a way to prevent allergies. Many countries now include updated infant feeding guidelines that support early introduction under a healthcare provider’s guidance.
Epinephrine Access
Epinephrine auto-injectors are still the first and best emergency response for anaphylaxis. Some countries have expanded their policies to allow more widespread stock epinephrine in schools and public spaces, though there’s still a push for better affordability, especially in the U.S.
- The Power of the Allergy Community Has Grown
When I last wrote in 2017, social media was already a place where families connected — but it was nowhere near as organized or far-reaching as it is now.
Today:
- There are thousands of support groups spanning Facebook, Instagram, TikTok, and forums.
- Advocacy organizations are more global and more connected — from Food Allergy Research & Education to international peer networks.
- Community voices increasingly shape policy, education materials, and research funding priorities.
What hasn’t changed?
The feeling that no matter where you live, this journey can feel isolating. That’s still real — and why communities like ours matter more than ever.
- Progress by Country — And Where Work Still Needs to Happen
Here’s a snapshot of progress around the world:
United States
- Better labeling laws and awareness campaigns
- More emergency medication access in public spaces
- Growing acceptance of allergy accommodations
Canada
- Updated allergen labeling
- Strong advocacy networks
- Growing research funding
United Kingdom & EU
- Allergen information regulations standardized
- Cross-contact warnings are common
- Some national education initiatives for schools
Australia
- Rising awareness
- Improvements in school policy
- Commitment to research
Other Countries
- In many parts of Asia, Africa, and Latin America, food allergy awareness and policy lags due to differences in healthcare infrastructure and public policy focus. Progress is happening, but it’s uneven — and voices from these regions are essential to a global conversation.
- What Still Needs to Change
Even with all we’ve gained, these challenges remain:
Understanding vs. Awareness
People might know the word “allergy,” but many still don’t understand:
- what reactions actually look like,
- how serious cross-contamination can be, or
- why accommodations matter.
Education must continue — not just awareness.
Access to Care
Not everyone has access to allergy specialists or treatments like OIT. Insurance, geography, and education all play a role.
Mental Health
This one has finally started getting the attention it deserves. Living with allergies impacts anxiety, community participation, school attendance, and everyday decisions — and mental health support is still too often overlooked.
- What I’d Change If I Could — Today
When I wrote that 2017 post, I talked about how we could do better as a community. In 2026, I would still say the same — but with more clarity:
- Educate with empathy
- Center voices from all countries and backgrounds
- Support mental health as aggressively as physical safety
- Make emergency care (like epinephrine) affordable for everyone
- Build policies that include everyone, not just a few
💬 In Closing — Let’s Hear From You
So much has changed since 2017. And yet, so much feels the same.
I want to hear from you — whether you’ve been here since the beginning or you’re just finding this community.
What changes have mattered most to you? What do you hope will change next?
Drop a comment, share your story, or send a message — and let’s build this conversation together.
📌 If You’re New Here: A Quick Start Guide
If you’re new to living with allergies — welcome. This blog is for you too. Here are three places to start:
- Understand your triggers and emergency plan
- Learn how labeling and cross-contact works in your country
- Connect with support groups — you’re not alone